32 results about "Cellular synthesis" patented technology

Disclosed herein are novel platinum-based analogs with a single substituted azole ligand: RN═NR7, wherein the RN═NR7 functional group is covalently bonded to the platinum through nitrogen of NR7. The analogs also have nitrogen donor ligands capable of forming hydrogen bonds with the bases in DNA or RNA, and one or more leaving groups which can be displaced by water, hydroxide ions or other nucleophiles, which is thought to form active species in vivo, and then, form cross-linked complexes between nucleic acid strands, principally between purines in DNA (or RNA), i.e., at the Guanine or Adenine bases, thereof. These platinum analogs may also be more easily transported into tumor cells, due to their increased lipophilicity and are likely to be useful as anti-neoplastic agents, and in modulating or interfering with the synthesis or replication or transcription of DNA or translation or function of RNA in vitro or in vivo, as they are potentially capable of forming a platinum coordinate complex with an intact or nascent DNA or RNA and thereby interfering with cellular synthesis, transcription or replication of nucleic acid polynucleotides.

The invention is directed compositions containing growth agents synthesized from cultured cells from skin. Skin cells such as keratinocytes and dermal fibroblasts are cultured in vitro in cell medium and in the course of culture the cultured cells synthesize and secrete agents into the cell medium. The medium containing agents are collected and incorporated into pharmaceutical or cosmetic preparations to treat an individual. The preparation is applied and has a rejuvenating effect on the cells and tissue.

This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE2 biosynthesis or PGE2 receptor antagonists alone, or in combination with other hematopoietic mobilization agents such as AMD3100 and G-CSF, increases the circulation of available HSPCs. Compounds that reduce the cellular synthesis of PGE2 include non-steroidal anti-inflammatory compounds such as indomethacin. Treatment ex vivo of HSPC with an effective amount of PGE2 or at least one of its derivatives such as 16,16-dimethyl prostaglandin E2 (dmPGE2), promotes HSPC engraftment. Similar methods may also be used to increase viral-mediated gene transduction efficacy into HSPC.

The invention relates to the field of cells and particularly relates to a culture medium and application thereof. The culture medium comprises a basic culture medium and unnecessary amino acids. The culture medium utilizes DMEMF12+ and the unnecessary amino acids, so that the nutrients are more abundant, and more abundant and wide sources are provided for synthesizing various active proteins by cells, and furthermore, the yield of proteins is improved. A condition culture medium obtained by collecting mesenchymal stem cells cultured by the culture medium provided by the invention is used for culturing the mesenchymal stem cells, and the quantity and the activity of the cells are remarkably improved.

The invention discloses a recombinant Escherichia coli zjut-ho1 and its application in the preparation of biliverdin, which is preserved in the Guangdong Microbial Culture Collection Center, with a preservation number of GDMCC No: 60372 and a preservation date of May 18, 2018. Address: 5th Floor, Building 59, Compound, No. 100 Xianlie Middle Road, Guangzhou City, Zip Code: 510075. The recombinant Escherichia coli expresses HO-1 with intracellular activity, and the recombinant Escherichia coli can be used as the HO-1 enzyme source, and hemin is used as the substrate to prepare biliverdin by biotransformation, which improves the production of biliverdin. way. Compared with the existing similar technologies, the present invention expresses ho1 from prokaryotic organisms in Escherichia coli of prokaryotic organisms, which has the advantages of high HO-1 activity and short culture period, and uses hemin as a substrate to make The yield of biliverdin is greatly improved, which is 2.6 times that of the recombinant Escherichia coli whole cell synthesis method.

Disclosed herein are novel platinum-based analogs with a single substituted imine ligand: R7RC═NR8, wherein the R7RC═NR8 functional group is covalently bonded to the platinum through nitrogen. The analogs also have nitrogen donor ligands capable of forming hydrogen bonds with the bases in DNA or RNA, and one or more leaving groups which can be displaced by water, hydroxide ions or other nucleophiles, which is thought to form active species in vivo, and then, form cross-linked complexes between nucleic acid strands, principally between purines in DNA (or RNA), i.e., at the Guanine or Adenine bases, thereof. These platinum analogs may also be more easily transported into tumor cells, due to their increased lipophilicity and are likely to be useful as anti-neoplastic agents, and in modulating or interfering with the synthesis or replication or transcription of DNA or translation or function of RNA in vitro or in vivo, as they are potentially capable of forming a platinum coordinate complex with a intact or nascent DNA or RNA and thereby interfering with cellular synthesis, transcription or replication of nucleic acid polynucleotides.

The invention provides a recombination porcine IFN (interferon) gamma-Fc fusion protein as well as a coding gene and expression, purification and inclusion body renaturation methods of the recombination porcine IFN alpha1-Fc fusion protein, which belong to the field of biology gene engineering. IFN gamma is synthesized of T cells and NK cells and has broad-spectrum antivirus and immune regulation functions and an important influence on the occurrence and development of diseases. Natural porcine IFN gamma expressed in an organism is insufficient for a large quantity of clinical studies and application, and the defect of fast clearing speed of the IFN gamma 1 in blood plasma exists. The recombination porcine IFN gamma-Fc fusion protein, which is provided by the invention, is suitable for an escherichia coli prokaryotic expression system, wherein a porcine IFN gamma part is an entire sequence of a porcine IFN gamma extracellular region, an Fc fragment part comprises a hinge region, a CH2 region and a CH3 region of an antibody, and the porcine IFN gamma part and the Fc fragment part are directly fused. The fusion protein provided by the invention has biological activity higher than that of the original protein IFN gamma, the half-life period of the fusion protein is greatly prolonged, and an opportunity is provided for industrial development of the fusion protein.

The invention discloses a method for efficiently synthesizing PHB by knocking out the rfaD gene, belonging to the fields of genetic engineering and fermentation engineering. In the invention, after knocking out the rfaD gene on the genome of Escherichia coli, the coding gene of the enzyme for synthesizing PHB is transformed into a bacterial strain to ferment and produce PHB. It was found that knockout of the rfaD gene could significantly improve the ability of Escherichia coli W3110, DH5α and JM109 to synthesize PHB, and the PHB volume production of WJW00 / pDXW‑8‑phaCAB was 3.95 and 3.66 times higher than that of the control bacteria W3110 / pDXW‑8‑phaCAB; WJD00 / The proportion of PHB synthesized by pDXW‑8‑phaCAB cells to cell dry weight increased by about 80% compared with the control bacteria, and the transformation rate increased by about 1.9 times; the ratio of PHB synthesized by WJJ00 / pDXW‑8‑phaCAB cells to cell dry weight increased by about 75% compared with the control bacteria , the conversion rate increased by about 1.8 times.

Disclosed herein are compositions, methods, and kits for cellular incorporation of non-natural amino acids into non-natural polypeptides. Also disclosed herein are compositions, methods, and kits for increasing the activity and yield of non-natural polypeptides synthesized from the cells.

The present invention is drawn, in part, to biocompatible compositions comprising a biocompatible polymer matrix and conditioned cell medium comprising i) a cell culture medium and ii) one or more agents synthesized by and secreted from one or more cells cultured in the cell culture medium, as well as therapeutic uses thereof, particularly in modulating bone and / or gum tissue growth.

The present invention relates to a metabolic network analysis method for streptomyces roseosporus as adaptomycin producing thalli, which comprises the following steps of: (1) constructing a central metabolic network pattern according to a glucolysis pathway, a pentose phosphate pathway, a citric acid cycle, an anaplerotic reaction, and a daptomycin synthesis reaction belonging to a cell synthesis reaction; (2) converting the metabolic network pattern into a matrix S (m*n), collecting a fermented liquid, measuring the cell dry weight, the glucose consumption rate, the daptomycin growth rate and the cell growth rate, and calculating an unknown flux according to know fluxes. In the present invention, the metabolic network analysis method is applied to the metabolic flux analysis of streptomyces roseosporus,the metabolic fluxes of intracellular reactions are calculated by measuring the metabolic flux of extracellular substances, and the distribution condition of glucose utilized by thalli to the glucolysis pathway, the pentose phosphate pathway, the citric acid cycle and the anaplerotic reaction is reflected. The present invention provides a new method for quantitatively researching the intracellular metabolic properties of streptomyces roseosporus.